Polycystic Ovary SyndromeNCT07591246
Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction
A study testing physical exercise program in people with Polycystic Ovary Syndrome and Non-Alcoholic Fatty Pancreatic Disease, run by Cairo University at 1 site in Egypt.
Trial summary
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease, Subclinical hypothyroïdism
- What is being tested?
- physical exercise program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 7 Mar 2026to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- PCOS
- fattty pancrease (non-alcoholic)
- subclinical hypothyroid (signifcant with thyroid stimauted horomone more than 10 mIU/L) and normal non-disordered free thyroxine horomones
Who cannot join
- cardiac disesase
- renal diseases
- respiratory disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo Unoversity
Giza
Ali Ismail, lecturer, 01005154209, allooka2012@gmail.com
About this study
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)
Read the detailed description
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease, Subclinical hypothyroïdism
- Being tested
- physical exercise program, usual care
- Medical subject headings
- Polycystic Ovary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physical exercise programBehavioural
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.
usual careOther
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month.
| Study group | Role | What they receive |
|---|---|---|
| group number 1 | Experimental | twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month. Receives: Behavioral: physical exercise program |
| group number 2 | Active comparator | twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin for six month Receives: Other: usual care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dehydroepiandrosterone
it is a hormone involved in synthesis of sex hormones
Measured: it will be measured after 6 months
Secondary outcomes (14)
ratio of leutinzing hromone to hormone of follicels stimulatting hormones
this ration express level of sex hormone
Measured: it will be measured after 6 months
testesterone
it is a sex horomone
Measured: it will be measured after 6 months
body mass index
it will be assessed on empty stomach and bladder
Measured: it will be measured after 6 months
waist circumference
it will be assessed on umblical levels
Measured: it will be measured after 6 months
blood gluocose
it will be assessed in fasting status
Measured: it will be measured after 6 months
glycated hemoglubin
it is an indiactor for longterm satus of blood gloucose
Measured: it will be measured after 6 months
insulin
it will be assessed in plasma
Measured: it will be measured after 6 months
thyroid stimualtined horomone
it will be assessed in plasma
Measured: it will be measured after 6 months
triglyceridess
it will be assessed in plasma
Measured: it will be measured after 6 months
low densitiy liopporotein
it will be assessed in plasma
Measured: it will be measured after 6 months
cholesteroll
it will be assessed in plasma
Measured: it will be measured after 6 months
high densitiy lipoporteins
it will be assessed in plasma
Measured: it will be measured after 6 months
alanine transaminase
it will be assessed in plasma
Measured: it will be measured after 6 months
aspartatte transaminase
it will be assessed in plasma
Measured: it will be measured after 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start7 Mar 2026
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Polycystic Ovary SyndromeStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Mohamed Ali ismail, Cairo University
- Investigators
- Ali MA Ismail, lecturer, Principal investigator, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07591246
- Sponsor's protocol ID
- IRB000-14233-74
- Status last verified
- May 2026
- First submitted
- 9 May 2026
- Last updated
- 15 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction
- ClinicalTrials.gov ID
- NCT07591246
- Acronym / sponsor ID
- IRB000-14233-74
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease, Subclinical hypothyroïdism
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 7 Mar 2026 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)
Detailed description
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group number 1 | Experimental | Behavioral: physical exercise programtwenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month. |
| group number 2 | Active comparator | Other: usual caretwenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin for six month |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- PCOS
- fattty pancrease (non-alcoholic)
- subclinical hypothyroid (signifcant with thyroid stimauted horomone more than 10 mIU/L) and normal non-disordered free thyroxine horomones
Key exclusion criteria (3 listed)
- cardiac disesase
- renal diseases
- respiratory disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physical exercise programtwenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month. | Behavioural | group number 1 |
| usual caretwenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month. | Other | group number 2 |
Primary outcome
Dehydroepiandrosterone
Time frame: it will be measured after 6 months
it is a hormone involved in synthesis of sex hormones
14 secondary outcomes
ratio of leutinzing hromone to hormone of follicels stimulatting hormones
Time frame: it will be measured after 6 months
testesterone
Time frame: it will be measured after 6 months
body mass index
Time frame: it will be measured after 6 months
waist circumference
Time frame: it will be measured after 6 months
blood gluocose
Time frame: it will be measured after 6 months
glycated hemoglubin
Time frame: it will be measured after 6 months
insulin
Time frame: it will be measured after 6 months
thyroid stimualtined horomone
Time frame: it will be measured after 6 months
triglyceridess
Time frame: it will be measured after 6 months
low densitiy liopporotein
Time frame: it will be measured after 6 months
cholesteroll
Time frame: it will be measured after 6 months
high densitiy lipoporteins
Time frame: it will be measured after 6 months
alanine transaminase
Time frame: it will be measured after 6 months
aspartatte transaminase
Time frame: it will be measured after 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
Related trials for Polycystic Ovary Syndrome
Recruiting
Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
PCOS (Polycystic Ovary Syndrome)
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingObservational study
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Polycystic Ovary Syndrome (PCOS)
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ali MA Ismail, lecturer principal investigator
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing physical exercise program in people with Polycystic Ovary Syndrome and Non-Alcoholic Fatty Pancreatic Disease, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ali MA Ismail, lecturer (01005154209, ali.mohamed@pt.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dehydroepiandrosterone (time frame: it will be measured after 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.